These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9768758)

  • 1. Crystal structure of mouse H2-M.
    Fremont DH; Crawford F; Marrack P; Hendrickson WA; Kappler J
    Immunity; 1998 Sep; 9(3):385-93. PubMed ID: 9768758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.
    Mosyak L; Zaller DM; Wiley DC
    Immunity; 1998 Sep; 9(3):377-83. PubMed ID: 9768757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.
    Alfonso C; Liljedahl M; Winqvist O; Surh CD; Peterson PA; Fung-Leung WP; Karlsson L
    Immunol Rev; 1999 Dec; 172():255-66. PubMed ID: 10631951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.
    Mellins ED; Stern LJ
    Curr Opin Immunol; 2014 Feb; 26():115-22. PubMed ID: 24463216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif.
    Lindstedt R; Liljedahl M; Péléraux A; Peterson PA; Karlsson L
    Immunity; 1995 Nov; 3(5):561-72. PubMed ID: 7584146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.
    Painter CA; Stern LJ
    Immunol Rev; 2012 Nov; 250(1):144-57. PubMed ID: 23046127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes.
    Belmares MP; Busch R; Wucherpfennig KW; McConnell HM; Mellins ED
    J Immunol; 2002 Nov; 169(9):5109-17. PubMed ID: 12391227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structure and function of the novel MHC class II molecule, HLA-DM.
    Gruneberg U; Van Ham SM; Malcherek G; Broker I; Melms A; Trowsdale J
    Biochem Soc Trans; 1997 May; 25(2):208S. PubMed ID: 9191252
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonclassical binding of formylated peptide in crystal structure of the MHC class Ib molecule H2-M3.
    Wang CR; Castaño AR; Peterson PA; Slaughter C; Lindahl KF; Deisenhofer J
    Cell; 1995 Aug; 82(4):655-64. PubMed ID: 7664344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to do with HLA-DO?
    van Ham M; van Lith M; Griekspoor A; Neefjes J
    Immunogenetics; 2000 Aug; 51(10):765-70. PubMed ID: 10970090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain.
    Stratikos E; Wiley DC; Stern LJ
    J Immunol; 2004 Jan; 172(2):1109-17. PubMed ID: 14707085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
    Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
    EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove.
    Zeng Z; Castaño AR; Segelke BW; Stura EA; Peterson PA; Wilson IA
    Science; 1997 Jul; 277(5324):339-45. PubMed ID: 9219685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice.
    Perraudeau M; Taylor PR; Stauss HJ; Lindstedt R; Bygrave AE; Pappin DJ; Ellmerich S; Whitten A; Rahman D; Canas B; Walport MJ; Botto M; Altmann DM
    Eur J Immunol; 2000 Oct; 30(10):2871-80. PubMed ID: 11069069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic peptide binding by class I and class II histocompatibility proteins.
    Stern LJ; Wiley DC
    Behring Inst Mitt; 1994 Jul; (94):1-10. PubMed ID: 7998902
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural and Biochemical Analyses of Swine Major Histocompatibility Complex Class I Complexes and Prediction of the Epitope Map of Important Influenza A Virus Strains.
    Fan S; Wu Y; Wang S; Wang Z; Jiang B; Liu Y; Liang R; Zhou W; Zhang N; Xia C
    J Virol; 2016 Aug; 90(15):6625-6641. PubMed ID: 27170754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
    Singh N; Van Kaer L
    J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.